Table 1.
Outcome of studies focusing on using nutraceuticals/dietary agents in treating HIV and COVID-19.
| Drug | HIV Outcomes | COVID-19 Outcomes | References |
|---|---|---|---|
| Ginkgo biloba (GB) and related compounds | ↑ HIV protease activity | --- | [86] |
| Show neuroprotective effects | --- | [88] | |
| --- | ↓ enveloped viral fusion Show antiviral activity against influenza virus |
[85,87] | |
| --- | Inhibit vital proteinase SARS-CoV-2 3CLpro | [91] | |
| Vitamin D supplementation | ↑ 25(OH)D concentration, correct vitamin D deficiency, improve immune response, and reduce mortality in HIV-positive patients | --- | [126,127,128] |
| Improve maternal health, birth outcomes, and infant growth among HIV-infected pregnant women | --- | [129] | |
| --- | Enhance the immune system, reduce risk, severity, and improve prognosis of SARS-CoV-2 infection | [71,72,73] | |
| --- | Prevent “cytokine storm” | [130,131,132,133,134] | |
| Vitamin C (ascorbic acid) | ↓ neuronal damage, but ↑ increase risks of drug interactions when used with multiple ARVs | --- | [81,84] |
| --- | Enhance immune system and reduce severity of SARS-CoV-2 infection | [72] | |
| --- | Intravenous (I.V.) vitamin C can be an effective treatment | [77] | |
| --- | Can be used concurrently with Quercetin as a prophylactic agent and treatment option | [78] | |
| --- | HDIVC provides no significant outcome in nCoV-2-induced ARDS | [79] | |
| Green tea (and other EGCG-containing compounds) | Antiviral effect against influenza, HIV, and hep C | --- | [93] |
| ↓ neuronal damage and apoptosis | --- | [96,98] | |
| ↓ neurotoxic effect of HIV proteins and can cross BBB | --- | [99] | |
| EGCG-containing nano-lipidic complexes enhance EGCG bioavailability by 2x | --- | [101] | |
| ↓ Aβ accumulation | --- | [135] | |
| Resveratrol | ↓ the HIV viral replication caused by Benzo(a)pyrene | --- | [36] |
| ↓ neurotoxic effects of HIV proteins | --- | [99] | |
| Inactivate ERK1/2 pathways, which reduces TNF-α and MCP-1 production in the hippocampus | --- | [103] | |
| Activate SIRT-1 in vivo by increasing NAD+ expression | --- | [106] | |
| --- | Show strong binding affinity to ACE2 in the lungs | [108] | |
| Resveratrol analog- 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol} (TIMBD) | ↓ HIV-gp120-induced neuroinflammation in SVG astrocytes | -- | [111] |
| Curcumin | ↓ ROS and proinflammatory cytokines | --- | [97] |
| ↓ neuronal apoptosis, especially through the HSP70 pathway | --- | [97,112] | |
| ↓ neuropathic pain | --- | [113] | |
| ↓ Ca2+ concentration in synaptosomes | --- | [121,122] | |
| ↓ viral replication exacerbated by extracellular vesicles (EVs) derived from cervical cancer cell lines (CASKI) | --- | [136] | |
| --- | Anti-inflammatory and pulmonary-protective effects on the infected lung tissues | [115] | |
| --- | ↓ interactions of SARS-CoV-2 spike proteins to ACE2 receptors in lungs | [124] | |
| --- | ↓ severity of SARS-CoV-2 infection | [116,125] |
HDIVC: High-dose intravenous vitamin C; EGCG: (-) epigallocatechin—3-gallate; GFAP: glial fibrillary acidic protein; NAD+: nicotinamide adenine dinucleotide; HSP70: heat shock protein 70; DRG: dorsal root ganglia; SIRT-1: sirtuins 1; GBLE: gingko biloba leaves extract; SVCT2: Na/vitamin C co-transporter isoform 2. ↑ increased; ↓ decreased.